Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
At NINGBO INNO PHARMCHEM CO.,LTD., our commitment to pioneering pharmaceutical solutions drives our intensive research into novel therapeutic agents. Our recent work focuses on the synthesis and evaluation of a new class of compounds: aryl-substituted 2-aminopyridine derivatives. These molecules are being explored for their significant potential in managing Alzheimer's disease (AD) by targeting the enzymatic pathways involved in neurodegeneration.
The core of our investigation lies in an innovative cascade reaction that efficiently synthesizes these complex 2-aminopyridine structures. This methodology, which combines 1,1-enediamines with vinamidinium salts, allows for the creation of diverse molecular architectures with high yields. Such synthetic efficiency is paramount in drug discovery, enabling the rapid generation and screening of multiple candidates.
The therapeutic strategy for AD often involves inhibiting acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). These enzymes are responsible for breaking down acetylcholine, a neurotransmitter vital for memory and cognition. By developing potent inhibitors of AChE and BChE, we aim to restore and enhance cholinergic function in the brains of AD patients. Our synthesized 2-aminopyridine derivatives have shown promising results in this regard, with compound 3m emerging as a particularly effective inhibitor.
The efficacy of compound 3m was rigorously tested. Kinetic studies confirmed its inhibitory mechanism, providing crucial data for understanding its interaction with target enzymes. This was complemented by advanced computational analyses. Molecular docking studies illustrated how 3m precisely fits into the active sites of AChE and BChE, predicting strong binding affinities. Molecular dynamics simulations further supported these findings, demonstrating the stability of the enzyme-inhibitor complexes and the compound's potential to act as a long-lasting therapeutic agent.
Beyond biological activity, the 'drug-likeness' of a compound is critical for its successful translation into a treatment. NINGBO INNO PHARMCHEM CO.,LTD. conducted in silico ADMET profiling for compound 3m. This assessment indicated that the molecule exhibits favorable characteristics for absorption, distribution, metabolism, excretion, and possesses a low predicted toxicity profile, making it a strong candidate for further development as an oral medication.
Our research into these novel 2-aminopyridine derivatives exemplifies NINGBO INNO PHARMCHEM CO.,LTD.'s dedication to addressing critical health challenges like Alzheimer's disease. By combining advanced synthetic chemistry with cutting-edge computational and biological evaluations, we are paving the way for new therapeutic strategies. The promising results associated with compound 3m underscore the potential of this chemical scaffold in the ongoing fight against neurodegenerative diseases.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
